“An Amazing Year for Breast Cancer Research”

January 25, 2018
Greg Guthrie, ASCO staff

The San Antonio Breast Cancer Symposium draws breast cancer experts from around the world into one place to share the latest research and progress.share on twitter In this podcast, Erica L. Mayer, MD, MPH, discusses some of the highlights from the 2017 symposium, held last month.

  • A study examined who may or may not benefit from long-term hormone therapy to prevent the cancer from coming back [2:20].

  • The PARP inhibitor Talazoparib may be a new targeted therapy to treat metastatic breast cancer in people with a BRCA1 or BRCA2 gene mutation [4:20].

  • Antibody drug conjugates, a type of targeted therapy, helped shrink tumors in people with HER2-positive and triple-negative breast cancer [5:42].

  • Research in supportive care looked at relieving joint discomfort and stiffness with acupuncture in patients receiving aromatase inhibitors [7:22].

  • A treatment called “ovarian suppression” may help preserve fertility in young women with breast cancer who are receiving chemotherapy [8:40].

Dr. Mayer is the Lineagotica Associate Editor for breast cancer.

This is a prerecorded audio podcast. It can be listened to online or downloaded to your computer. A transcript of this podcast is also available. For more information, visit the Lineagotica podcast page.